Kornimate/medical-research-clean huggingface dataset:
exercise and pain in ayacs

Conditions: AYA Cancer Survivors

Summary: the purpose of this study is to demonstrate that integration of exercise intervention into standard post-cancer directed treatment care will improve patient reported pain, decrease the need for medications to manage chronic pain and improve functional and psychosocial outcomes in survivors of cancers in adolescents and young adults (aya). our central hypothesis is that integration of exercise interventions into standard post-cancer directed treatment care will be acceptable and feasible while improving patients' pain, decreasing the cumulative dose of pain medication and improving patients' functional and psychosocial outcomes as compared to patients who only receive standard post-cancer directed treatment care.


Eligibility criteria:
inclusion criteria: 1. male and female aya cancer survivors diagnosed with any type of cancer between the ages of 15 and 39 years old 2. aya cancer survivors who have completed all standard/planned cancer treatment and are stable at the time of recruitment 3. aya cancer survivors are \< 1-year post cancer therapy 4. aya cancer survivors who have chronic pain (pain will be self-reported by the participant, will have to be ≥1 on a scale of 10 and lasting for 3 months or longer) 5. aya cancer survivors who are age ≥18 years old at the time of enrollment 6. aya cancer survivors who are and who are not non-ambulatory/wheelchair bound. 7. aya cancer survivors must be able to speak, read and understand the english language 8. aya cancer survivors must be able to provide and understand informed consent 9. aya cancer survivors must be able to attend three visits (baseline, 8 and 16-week follow-up) at the penn state health milton s. hershey medical center 10. aya cancer survivors must have access to a computer with wifi, smartphone with wifi or tablet with wifi note: the agreement of the attending oncologist will be required for the participation of aya cancer survivors eligible for this study. exclusion criteria: 1. aya cancer survivors who have not completed all standard/planned cancer treatment and/or not in complete remission at the time of recruitment 2. aya cancer survivors who are \> 1-year post cancer therapy 3. aya cancer survivors who are \< 18 years old at the time of enrollment 4. cancer survivors who have evidence of an absolute contraindication to complete any of the physical assessments in their medical record. this exclusion criterion is at the oncologist's discretion when research staff will contact the medical oncologist via secure email or secure message through the electronic medical record for approval to approach their patients for the study and for medical clearance. the oncologists can update this information at any time during the study if there is evidence of an absolute contraindication to complete any of the physical assessments. 5. aya cancer survivors who have history of refractory or recurrent cancer 6. aya cancer survivors who are unable to speak, read, and understand the english language
efficacy and safety of ruxolitinib in patients with myelofibrosis

Conditions: Myelofibrosis

Summary: ruxolitinib is a janus kinase (jak) 1/2 inhibitor currently used in the treatment of myelofibrosis (mf). ruxolitinib confirmed improvements in splenomegaly, mf-related symptoms and survival benefit in comfort and jump studies. at present, the real-world data on the efficacy and safety of ruxolitinib in the treatment of mf in china is still insufficient. the aim of this study was to evaluate the efficacy and safety of ruxolitinib in patients with mf and to provide guidance for the usage of ruxolitinib in mf in china.this was a retrospective, multicenter study of mf patients who received ruxolitinib treatment in shandong province from august 2012 to december 2021. data were analyzed using spss. overall survival (os) and event-free survival (efs) were estimated using the kaplan- meier method.


Eligibility criteria:
inclusion criteria: 1. male or female patients aged ≥18 years with a diagnosis of primary or secondary mf by world health organization and international working group for myeloproliferative neoplasms research and treat- ment (iwg-mrt) criteria; 2. received ruxolitinib treatment for ≥3 months. exclusion criteria: 1. malignant tumors with other progression or myelofibrosis secondary to other diseases; 2. exclude myelofibrosis patients after splenectomy; 3. patients with poor compliance with case follow-up or lost to follow-up.
weight-bearing tomosynthesis in evaluation of foot/ankie

Conditions: Arthritis

Summary: this study aims to compare digital tomosynthesis with radiography and weight-bearing ct as an imaging technique to assess arthritis in the foot and ankle.

the overall goal of this study is to improve radiologic evaluation of foot and ankle arthritis. today's standard of care, radiography, provides limited two-dimensional evaluation of joint alignment, arthritic changes, posttraumatic changes, and congenital deformities due to overlapping bone densities. evaluation is even more limited in post-surgical patients due to overlapping metallic hardware. computed tomography (ct), the current problem-solving tool, offers more "level-by-level" three dimensional information, but is fraught with additional cost, additional radiation dose, beam-hardening artifacts from hardware, and the need for additional equipment. most importantly, patients are not weight-bearing during conventional ct, therefore masking the true extent of malalignment or arthritic joint space narrowing. at the university of washington, physicians attempt to overcome the last problem by performing simulated weight-bearing ct. the study proposes an alternate solution to this problem using a novel application of an old method, digital tomosynthesis. specific aims of the study are 1) to compare radiography, tomosynthesis, and simulated-weight bearing ct in their ability to detect foot/ankle malalignment, 2) to compare the abilities of these three modalities to detect arthritis changes such as joint space narrowing, osteophytes, and subchondral cysts, and 3) to compare their abilities to detect bony deformities such as acute fracture, old fracture deformity, or partial fusion (post traumatic or post surgical). radiographic assessment will be correlated with clinical outcome using clinical notes and functional outcome such as the lower extremity functional scale (lefs) questionnaire. successful results from this initial study will have the potential to change practice paradigm in how to image foot and ankle arthritis.

Eligibility criteria:
inclusion criteria: 1. adult age (18 years or older) 2. clinical orthopedic surgery follow-up notes available at university of washington 3. ability to complete the lower extremity functional scale (lefs) or equivalent questionnaire at the time of the study, a well established survey to test for functional ability in lower extremity exclusion criteria: 1. inability to use the simulated weight bearing ct machine due to pain 2. prior complete osseous fusion of foot/ankle joints 3. prior total ankle arthroplasty 4. pregnancy
acceptability study by patients admitted for suicide and by medical staff for clinical data collection through an e-health platform

Conditions: Suicide, Attempted

Summary: the study goal is to determine the feasbility and interest of monitoring mental health and non mental health related simptoms in outpatients in order to prevent suicide.

taking into account the strengths and pitfalls of existing suicide risk assessment methods, we have designed a system capable to combine ema and continuous monitoring of patients using the smartphone's and/or wearable's sensors and data entry in order to monitor and predict suicide risk. for example, both poor sleep quality and disturbed appetite are clinical markers of depression, with a bidirectional relationship. their changes could precede the increase of suicidal behavior as sleep and appetite are both influenced by mood state and regulated by the serotonergic system. our hypothesis is that tracking mental health simptoms regularly through self-report could serve as a consistent and non-biased shortcut to assess mood state, its biological underpinnings and could potentially predict suicidal behavior.

Eligibility criteria:
to be eligible for the study, patients must be 18 years or older, attend an outpatient clinic or emergency departments of participating clinical services and owning an android or ios smartphone
a long term safety study of apricitabine in hiv-infected patients

Conditions: HIV Infections

Summary: this study will examine the long term safety of apricitabine in hiv-1 infected patients from studies avx-301 or avx-302. eligible patients are those who have either (a)completed studies avx-301 or avx-302; or (b)met the criteria for virological failure/lack of response, and consequently wish to withdraw early from studies avx-301 or avx-302.

the clinical study avx-301 studies the efficacy and safety of 800mg and 1200mg bid atc in combination with an optimized background in patients who are hiv-1 infected and have failed treatment with emtricitabine or lamivudine and have confirmed m184v/i mutation. patients who do not achieve at least a 0.5 log10 copies/ml decrease in plasma hiv rna by week 16, or who experience a \>1.0 log10 copies/ml increase (confirmed on two separate occasions at least one week apart) in plasma hiv rna from nadir at or after week 16, are eligible for screening for entry into this study. in addition, patients who complete study avx-301 are also eligible for screening. the clinical study avx-302 is similar and studies the efficacy and safety of a single dose of atc (determined in avx-301). patients in avx-302 who experience virologic failure or lack of virologic response will similarly be eligible for screening for entry into this study. in addition, patients who complete study avx-302 are also eligible for screening. this is a phase 3, open-label, multi-center study of up to 96 weeks duration. patients will receive for up to 96 weeks open-label atc, initially at a dose of 1200mg orally bid. following selection of the optimum atc dose in protocol avx-301 and termination of one of the two atc doses (800mg or 1200mg orally bid) in protocol avx-301, patients in this protocol will be transferred to the optimum dose, if required. the total number of patients expected to be enrolled in studies avx-301 and avx-302 is approximately 1866 in total.patients will receive atc orally in combination with their existing art. background antiretroviral therapy (art) may be revised at any time during the study at the discretion of the investigator but must not include lamivudine, emtricitabine, zalcitabine or any other deoxycytidine analogue nrti. the study will examine the safety and tolerability of long term treatment with apricitabine in combination with other art.

Eligibility criteria:
inclusion criteria: * patients who complete studies avx-301 or avx-302 or :patients who meet the criteria for virologic failure/lack of response in study avx-301 or avx-302 * 18 years of age, or older * male, or non-pregnant, non-breastfeeding female patients, who agree to comply with the applicable contraceptive requirements of the protocol. exclusion criteria: * prior withdrawal from avx-301 or avx-302 * current acute or chronic hepatitis b virus infection * current treatment for hepatitis c virus infection * renal function not adequate

Keywords: hiv-1 infection nrti resistance m184v mutation reverse transcriptase apricitabine drug resistance safety and tolerability therapy failure treatment experienced
a safety and acceptability study of a vaginal ring microbicide delivery method

Conditions: HIV Infections

Summary: the proposed study is a multi-centre, open-label crossover study to assess the safety and acceptability of a silicone elastomer vaginal ring (containing no drug) when inserted for a 12 week period in 200 healthy, sexually active women.


Eligibility criteria:
inclusion criteria: * female, age 18-35 years * willing and able to provide written informed consent * hiv-uninfected and otherwise healthy * self-reported sexually active * on a stable hormonal contraceptive regimen * regular menstrual cycle * willing to refrain from use of vaginal products or objects during the study exclusion criteria: * currently pregnant or last pregnancy within 3 months prior to enrollment * currently breast-feeding * participated in any other research study within 30 days prior to enrollment; * symptomatic untreated vaginal infections within 2 weeks prior to enrollment * presence of abnormal physical finding on the vulva, vaginal walls or cervix * history of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding, urethral obstruction; * pap smear result at screening that requires cryotherapy, biopsy, treatment (other than for infection), or further evaluation * unexplained, undiagnosed abnormal bleeding per vagina, bleeding per vagina during or following vaginal intercourse, or gynecologic surgery within 90 days prior to enrollment * any serious acute, chronic or progressive disease

Keywords: hiv-1 hiv seronegativity
gastrointestinal microflora and serum metabolomics in patients with pancreatic cancer and chronic pancreatitis

Conditions: Pancreatic Cancer; Chronic Pancreatitis

Summary: the investigators plan to collect throat swabs, saliva, feces and serum samples from pancreatic cancer patients, chronic pancreatitis patients and healthy people and clarify the characteristics of oral flora and serum metabolome of pancreatic cancer patients.


Eligibility criteria:
inclusion criteria: 1.pathologic diagnosis of pancreatic ductal adenocarcinoma；diagnosis of cp defined as having obvious morphological features of cp (i.e., the presence of pancreatic calcifications on ct scan and/or magnetic resonance cholangiopancreatography)；other benign disease populations without pancreatic lesions. exclusion criteria: 1. pregnant women. 2. patients with coagulation disorders who are unable to undergo blood tests. 3. have a history of using antibiotics or probiotics within the past 3 months.
risk factors for distal caries of second molars adjacent to mandibular impacted third molars

Conditions: Decay, Dental; Impacted Third Molar Tooth

Summary: distal surfaces of second molars adjacent to wisdom teeth are always at risk for caries and external root resorption. the incidence of caries is high, especially in partially impacted third molars in mesioangular and horizontal positions. in this study, investigators aimed to examine the caries correlation in the distal second molar with the age, gender, side and dmft scores of the participants.


Eligibility criteria:
inclusion criteria: * being between 20 and 40 years old * having a surgery appointment for removal of the partially impacted third molar which is mesioangular or horizontal position * having an orthopantomogram on the database * and having a second molar adjacent to the impacted third molar exclusion criteria: * crowned or restored the second molar * any surgery related to the contact area * any pathology related to the second or third molar * a radiological artifact on the contact area * insufficient radiological quality for the evaluation.
the effect of fasting on serum osmolarity in diabetic patients

Conditions: Type2 Diabetes

Summary: in ramadan, muslims perform a special kind of fasting. their fasting start with the first lights of the sunrise and end with the sunset. especially in summer, it is a real challenge, as the time for fasting might be as long as 18 hours, and hot weather might cause severe dehydration. this might be dangerous, especially in patients with diabetes. serum osmolarity is a good surrogate marker to evaluate the body's fluid content. we aimed to investigate if summertime ramadan fasting causes further fluid loss in patients with type 2 diabetes.

till recently, it was assumed that patients with type 2 diabetes have to eat frequently, especially to avoid hypoglycemia, which is still true if they are using sulphonylurea or insulin. especially because patients with diabetes often have one or more diabetic complications, they were advised against ramadan fasting, as it is not allowed to eat or drink anything for long hours. there are increasing data supporting intermittent fasting, where individuals won't eat anything for 12-18 hours but are permitted to drink sugar-free beverages. the new antihypoglycemic agents have the advantage of causing very low or no hypoglycemia, which allows these patients to eat less frequently. there are studies about the metabolic effect of intermittent fasting in patients with type 2 diabetes, but we don't have enough data for the safety of religious fasting where no kind of fluid intake is allowed. in this study, we aimed to investigate the effect of fasting on the fluid status of diabetic patients. to this effect, we used serum osmolarity to determine fluid status. the patients who preferred to fast were our study group, and the patients who were healthy otherwise but preferred not to fast were our control group. in ramadan, contrary to the customary practice of intermittent fasting, fasting starts with the sunrise and continues till sunset. we planned to take the first blood sample at 10 am and the second blood sample at 06 pm in both groups and compare the serum osmolarity accordingly.

Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes * will accept to give two different blood samples * will prefer to fast during ramadan ( for the intervention group) * will prefer not to fast during ramadan ( for the control group) * have good glycemic control exclusion criteria: * if the patients are not eligible for fasting

Keywords: fasting, osmolarity, fluid loss
phase ii study of durvalumab(medi4736) + tremelimumab in pulmonary sarcomatoid carcinoma

Conditions: HNSCC; Head and Neck Neoplasms

Summary: phase ii study of durvalumab+/- tremelimumab in patients with recurred metastatic head and neck squamous cell carcinoma

open, multicenter, single arm, phase ii, biomarker driven umbrella trial for head and neck squamous cell carcinoma

Eligibility criteria:
inclusion criteria: * 1. recurrent or metastatic hnscc, regardless of pd-l1 or hpv status 2. age ≥20 3. ecog ps 0-1 4. ineligibility for local therapy (surgery or radiotherapy) 5. prior palliative chemotherapy including platinum-based chemotherapy. when recurred within 6 months of definitive/neoadjuvant/adjuvant chemo- or chemoradiation, the chemotherapy is considered a line of therapy 6. at least one measurable lesion by recist ver 1.1 7. adequate organ function for treatment * absolute neutrophil count (anc) ≥1000 cells/mm3 * hemoglobin: ≥ 9.0 g/dl * platelets ≥100,000 cells/mm3 * estimated creatinine clearance ≥40 ml/min, or serum creatinine \<1.5 x institution upper limit of normal * bilirubin ≤1.5 x upper limit of normal (uln) * ast (sgot) ≤2.5 x uln (5.0 x uln if hepatic metastases) * alt (sgpt) ≤2.5 x uln (5.0 x uln if hepatic metastases) 8. 12-lead electrocardiogram (ecg) with normal tracing or non-clinically significant changes that do not require medical intervention 9. the patient has provided signed informed consent exclusion criteria: * 1. previous treatment with pd-1 or pdl-1 inhibitors 2. nasopharyngeal carcinoma 3. cytotoxic chemotherapy within 3 weeks of study entry; immunotherapy or investigational drug within 5 half-lives of study entry 4. any major operation or irradiation within 4 weeks of baseline disease assessment. palliative radiation is allowed 5. symptomatic brain metastasis 6. patients with known interstitial lung disease 7. patients with uncontrolled or significant cardiovascular disease 8. previous or concurrent malignancy (except for basal or squamous cell skin cancer and/or in situ carcinoma of the cervix, thyroid cancer treated curatively) without evidence of recurrence for at least 3 years prior to study entry. 9. pregnant or breast-feeding women 10. systemic immunosuppressive therapy 11. active autoimmune disease 12. patient who have an active systemic fungal and/or known viral infection (for example, human immunodeficiency virus antibodies, hepatitis b surface antigen, or hepatitis c antibodies) (inactive hbv carrier with adequate prophylactic antiviral agent can be enrolled) 13. body weight \<30kg 14. other severe acute or chronic medical condition or laboratory abnormality that may increase the risk associated with trial participation

Keywords: biomarker driven umbrella trial durvalumab + tremelimumab combination treatment
non-invasive identification of colorectal cancer and adenomas in early stages

Conditions: Colorectal Cancer

Summary: the nice study is a prospective, multi-site study to train and validate a blood-based, glycoproteomic test for the early detection of advanced adenoma and colorectal cancer by collecting blood samples and associated relevant clinical information from average-risk participants who undergo routine screening colonoscopy as well as participants undergoing colonoscopy for surveillance or diagnostic indications

intervenn is using its glycoprotein profiling technology platform that couples high-resolution liquid chromatography (lc)-mass spectrometry (ms) with an artificial intelligence (ai), neural network (nn)-based high-throughput data processing software to identify patterns uniquely associated with colon adenoma and colon adenocarcinoma in order to detect (pre)cancerous events early. the purpose of this prospective multi-center observational study is to train and validate a blood-based, glycoproteomic test for the early detection of advanced adenoma and colorectal cancer by collecting blood samples and associated relevant clinical information from average-risk participants who undergo routine screening colonoscopy as well as participants undergoing colonoscopy for surveillance or diagnostic indications.

Eligibility criteria:
inclusion criteria: 1. male or female subjects between the ages of 45-85. 2. able to provide an informed consent and who understand and agree to all study procedures required 3. subject is scheduled or will soon be scheduled to receive a colonoscopy as ordered by their doctor. exclusion criteria: 1. any active malignancy 2. any other illness that in the opinion of the investigator, makes the subject not a good candidate for the study.